Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis
- 11 May 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 165 (2) , 411-414
Abstract
Background Post‐kala‐azar dermal leishmaniasis (PKDL) constitutes a parasite reservoir important in the transmission of visceral leishmaniasis (VL). Unacceptable treatment regimens and increasing drug resistance blight control programmes. The success of oral miltefosine in VL prompted a clinical, histopathological and parasitological study of this drug in PKDL. Objectives To define the dose and duration of miltefosine for treatment of PKDL. Methods Twenty‐six patients confirmed by slit‐skin smear, histopathology and molecular tests were enrolled in the study. They received miltefosine capsules 50 mg thrice daily after food. Treatment was for 60 days with a provision to increase by 30 days if a responder had not attained a cure. Cure was ascertained by clinical and histopathological examination, and measuring parasite burden using real‐time polymerase chain reaction. Results Twenty‐four patients with a wide range of parasite burden completed the study. Twenty‐three achieved a cure giving an initial cure rate of 96% (95% confidence interval 79–99%). Sixteen patients were cured with 50 mg thrice daily, 13 in 60 days and three within 90 days. In seven cases, miltefosine had to be reduced, because of gastrointestinal intolerance, to 50 mg twice daily to a total of 180 capsules. Lesional parasites were undetectable at 1 month post‐treatment. Treatment was safe with no relapses at 1‐year follow‐up. Conclusion Oral miltefosine, 50 mg thrice daily for 60 days or twice daily for 90 days, could be an effective treatment for PKDL.Keywords
This publication has 15 references indexed in Scilit:
- Post-kala-azar Dermal Leishmaniasis: Facing the Challenge of Eliminating Kala-Azar from South Asia2010
- Quantification of Parasite Load in Clinical Samples of Leishmaniasis Patients: IL-10 Level Correlates with Parasite Load in Visceral LeishmaniasisPLOS ONE, 2010
- Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasisClinical and Experimental Dermatology, 2007
- Development of miltefosine as an oral treatment for leishmaniasisTransactions of the Royal Society of Tropical Medicine and Hygiene, 2006
- Visceral Leishmaniasis, or Kala Azar (KA): High Incidence of Refractoriness to Antimony Is Contributed by Anthroponotic Transmission via Post‐KA Dermal LeishmaniasisThe Journal of Infectious Diseases, 2006
- Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosineTransactions of the Royal Society of Tropical Medicine and Hygiene, 2006
- Leishmaniasis: drugs in the clinic, resistance and new developmentsDrug Resistance Updates, 2004
- Post-kala-azar dermal leishmaniasisThe Lancet Infectious Diseases, 2003
- A simple and sensitive test for field diagnosis of post kala-azar dermal leishmaniasis.British Journal of Dermatology, 2001
- Trial of oral miltefosine for visceral leishmaniasisThe Lancet, 1998